MMRGlobal, Inc. has received a new biotechnology patent in Hong Kong. The patent entitled 'Method and Composition for Altering a B Cell Mediated Pathology' protects certain methods of manufacturing compositions for B-Cell vaccines used in the fight against lymphoma and potentially other forms of cancer. In less than two years, The company had already entered into a $13 million licensing agreement with Big Pharma.

Meanwhile, the company is continuing to diligently concentrate its efforts on building both its biotech and health information technology patent portfolios. MMR is already licensing portions of its biotech portfolio, including a remaining $12 million portion of a $13 million non-exclusive licensing agreement with a major biopharmaceutical company.